A Phase 2a, Blinded, Randomized, Placebo-Controlled Study of PORT-77 Administered Orally to Adults With Erythropoietic Protoporphyria
Latest Information Update: 23 May 2025
At a glance
- Drugs PORT 77 (Primary)
- Indications Erythropoietic protoporphyria
- Focus Therapeutic Use
- Acronyms GATEWAY
- Sponsors Portal Therapeutics
Most Recent Events
- 23 May 2025 New trial record